Elite Pharmaceuticals (ELTP) investor relations material

Executive summary

• Q1 FY2027 revenue was $32.4M, down 19.5% year over year from a record prior-year quarter; operating income was $7.5M, down 65%.

• Net income attributable to common shareholders was $5.9M.

• Product volumes and market shares advanced while pricing stabilized; pipeline investment and launches continued.

Financial highlights

• Revenue was $32.4M, down $7.9M year over year; gross profit fell 50% to $13.5M and gross margin declined to 42% from 68%.

• Operating income was $7.5M, down 65% from $21.7M, mainly reflecting lower margins on generic Vyvanse® sales.

• Net income was $5.9M versus a $5.9M prior-year net loss, aided by a favorable change in derivative warrant fair value.

• Operating cash flow was $10.1M vs. $14.8M year over year; cash and restricted cash totaled $39.4M at quarter-end.

• R&D expense was $2.0M vs. $1.7M year over year.

Outlook and guidance

• Management expects product development and pipeline launches to support future revenue and profit growth; no quantified near-term target was stated.

• Methadone launched in April and ropinirole ER in July; both are expected to contribute to future growth.

• Management expects Nasdaq uplisting as a standalone path or alongside an acquisition, with completion or near-finalization estimated by February 2027.

• Oxycodone ER launch by August 2027 depends on resolving an FDA anti-abuse issue; an undisclosed anticoagulant may launch in 2028, subject to negotiations.